GE Capital

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, specializing in the development and commercialization of diagnostic blood tests designed to enhance personalized medicine. The company focuses on adherence testing for psychiatrists and chemotherapeutic drug monitoring for oncologists. Its product line, known as MyCare, includes tests such as MyCare Psychiatry, which helps determine the appropriate antipsychotic dosage for patients; MyCare Oncology, which optimizes chemotherapy exposure; and MyCare Neurology, for assessing the effects of neurological drugs. Specific tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are used to manage treatment for various cancers and conditions. Saladax markets its products through distributors across the Asia Pacific, European Union, Middle East, and North Africa, as well as through direct sales in select regions. With over 15 years of experience, Saladax aims to provide convenient and cost-effective solutions for therapeutic drug monitoring, enabling physicians to tailor drug dosing to individual patient needs.

SunGard Data Systems Inc. is a global provider of software and technology services, primarily serving the financial services, education, and public sectors. The company operates through four segments: Financial Systems, Higher Education, Public Sector, and Availability Services. The Financial Systems segment offers solutions that automate processes related to trading, investment portfolio management, and asset accounting, catering to financial institutions, corporate treasury departments, and energy companies. The Higher Education segment provides enterprise resource planning and administrative solutions for colleges and universities, addressing their academic and operational needs. The Public Sector segment focuses on software and services for K-12 education, government agencies, and public institutions, supporting various administrative functions and public safety initiatives. The Availability Services segment ensures uninterrupted access to critical IT systems through recovery and managed services. SunGard offers its solutions through traditional software and cloud-based models, emphasizing technology consulting and implementation services. Founded in 1983 and based in Wayne, Pennsylvania, SunGard Data Systems Inc. operates as a subsidiary of SunGard Holdco LLC.

Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company based in Blue Bell, Pennsylvania, focused on discovering and developing small molecule drug therapies for immune system disorders. The company's lead candidate, ACH-4471, is a factor D inhibitor currently undergoing Phase II clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy. Additionally, Achillion is developing two other factor D inhibitors, ACH-5228 and ACH-5548, both in Phase I clinical trials for PNH and other complement-mediated diseases. The company also has licensing agreements with Ora, Inc. for the development of ACH-702, and with GCA Therapeutics, Ltd. for elvucitabine, a treatment for hepatitis B and HIV. Founded in 1998, Achillion aims to advance its portfolio of therapies targeting the complement system, which plays a crucial role in various immune-related conditions.

CB Technologies, Inc. (www.cbtech.com), is a leading provider of electronic data capture, e-business consulting, and integration services to the pharmaceutical and healthcare industries, with 128 employees in its headquarters in West Chester, Pennsylvania and Boston, Massachusetts. Inc. Magazine named the firm one of the 500 fastest growing privately held companies in America for the past two consecutive years. Applications created by CB are currently in use at leading pharmaceutical/healthcare companies and support thousands of users worldwide.